Scholarlink

<p>Angiogenesis is an early marker of tumor growth, and a key process that promotes tumor growth, progression and metastasis. Accurate and early evaluation of tumor angiogenic activity using non-invasive imaging modalities is crucial for tumor diagnosis, therapeutic monitoring, and prognosis prediction. In this study, we reported a sensitive, specific, and biocompatible magnetic resonance (MR)/ fluorescence (FL) bimodal contrast agent for targeting aminopeptidase-N (APN/CD13) overexpressed in tumor angiogenesis. The obtained cNpQDs exhibited potent T1-weighted imaging capabilities (r<sub>1</sub> = 11.1081&#xa0;mM<sup>−1</sup>·s<sup>−1</sup>) and effective photoluminescence emission. The CD13 binding affinity of the peptide cNGR was evaluated using a HUVEC cell-based receptor binding test, in which the internalization rate of cNpQDs was 10.17 times higher than that of pQDs. Furthermore, in vivo experiments indicated that MR/FL imaging of cNpQDs significantly enhanced the contrast of tumor angiogenesis. Biocompatibility studies provide evidence that cNpQDs has no obvious toxicity in vivo. These findings indicated that cNpQDs may serve as an efficiency MR/FL bimodal contrast agent, offering a potential alternative for assessing tumor angiogenesis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Biologically inspired bimodal imaging agent incorporating quantum dots and magnetic nanoparticles targeting tumor angiogenesis

  • 期刊论文

  • 发表日期：

    2026年4月29日

查看全文
  • Qi Guo,
  • Menglin Wu,
  • Jiang Li,
  • Guoping Xu,
  • Xinhong Wu,
  • Xiudi Lu,
  • Xunxiao Zhao,
  • Guilai Li,
  • Xuening Zhang,
  • Xue Li,
  • Yang Zhao

摘要

Angiogenesis is an early marker of tumor growth, and a key process that promotes tumor growth, progression and metastasis. Accurate and early evaluation of tumor angiogenic activity using non-invasive imaging modalities is crucial for tumor diagnosis, therapeutic monitoring, and prognosis prediction. In this study, we reported a sensitive, specific, and biocompatible magnetic resonance (MR)/ fluorescence (FL) bimodal contrast agent for targeting aminopeptidase-N (APN/CD13) overexpressed in tumor angiogenesis. The obtained cNpQDs exhibited potent T1-weighted imaging capabilities (r1 = 11.1081 mM−1·s−1) and effective photoluminescence emission. The CD13 binding affinity of the peptide cNGR was evaluated using a HUVEC cell-based receptor binding test, in which the internalization rate of cNpQDs was 10.17 times higher than that of pQDs. Furthermore, in vivo experiments indicated that MR/FL imaging of cNpQDs significantly enhanced the contrast of tumor angiogenesis. Biocompatibility studies provide evidence that cNpQDs has no obvious toxicity in vivo. These findings indicated that cNpQDs may serve as an efficiency MR/FL bimodal contrast agent, offering a potential alternative for assessing tumor angiogenesis.